Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,285.00

Eli Lilly and Company (NYSE:LLY) had its price objective increased by Deutsche Bank Aktiengesellschaft from $1,200.00 to $1,285.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also recently commented on LLY. Cantor Fitzgerald upped their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. National Bank Financial set a $1,286.00 target price on Eli Lilly and Company in a research note on Monday, December 1st. Bank of America reduced their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a report on Monday, December 15th. Finally, Jefferies Financial Group upped their price target on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,217.71.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,015.48 on Monday. The firm has a market cap of $960.02 billion, a price-to-earnings ratio of 44.25, a PEG ratio of 0.94 and a beta of 0.39. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a 50-day moving average price of $1,051.24 and a 200 day moving average price of $903.76.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter last year, the firm earned $5.32 EPS. The company’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 26.14%.

Hedge Funds Weigh In On Eli Lilly and Company

A number of large investors have recently modified their holdings of the business. Norges Bank bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $12,976,634,000. Laurel Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares in the last quarter. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Finally, Amundi raised its position in Eli Lilly and Company by 27.1% during the third quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after acquiring an additional 964,675 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion, adding circular‑RNA and in‑vivo CAR‑T capabilities to diversify beyond GLP‑1s and bolster its next‑gen RNA/cell therapy pipeline. Read More.
• Positive Sentiment: Lilly advanced obesity and cardiometabolic candidates: eloralintide moved into Phase 3 (expanding its obesity franchise) and solbinsiran showed Phase 2 progress in high‑risk cholesterol — both increase future revenue optionality. Read More. Read More.
• Positive Sentiment: Strong fundamentals: 2025 results and management guidance underpin upside (large revenue/EPS jumps and 2026 guidance lifted), supporting long‑term earnings growth expectations. Read More.
• Positive Sentiment: Institutional buying: Fisher Asset Management increased its stake, signaling confidence from a major investor. Read More.
• Neutral Sentiment: Lilly inked a partnership with gene‑editing start‑up Seamless Therapeutics to broaden R&D approaches — potential upside, but early and dilutive timelines make near‑term impact uncertain. Read More.
• Neutral Sentiment: Multiple bullish commentaries and buy‑thesis pieces highlight secular GLP‑1 leadership and pipeline depth — helpful for sentiment but not new fundamental data. Read More. Read More.
• Negative Sentiment: Valuation and momentum risk: after a >60% six‑month rally and a high multiple, investors may be booking gains; stretched valuation raises sensitivity to any slowdown in GLP‑1 adoption or clinical setbacks. Read More.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.